Plicni ordinace s.r.o.
- Address
- Nadrazni 582, 580 01 Havlíčkův Brod, Czechia
Plicni ordinace s.r.o. - COPD Research Center
Plicni ordinace s.r.o. is a specialized pulmonary research center focused on advancing treatment options for patients with Chronic Obstructive Pulmonary Disease (COPD). The center has established expertise in evaluating novel therapeutic approaches and conducting long-term safety studies for patients with moderate to severe COPD, including those with chronic bronchitis.
- Long-term safety and tolerability studies of biologic therapies, including itepekimab for COPD management
- Add-on therapy trials evaluating CHF6001 DPI in combination with triple maintenance therapy (ICS, LABA, LAMA)
- Exacerbation reduction studies in former smokers with moderate-to-severe COPD
The research facility specializes in comprehensive evaluation of COPD exacerbation rates and innovative combination therapies. Their clinical trial portfolio demonstrates particular strength in assessing add-on treatments to standard triple therapy regimens and evaluating the efficacy of emerging biological agents in reducing moderate and severe exacerbations over extended treatment periods of up to 52 weeks.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Plicni ordinace s.r.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Itepekimab in Moderate-to-Severe Chronic Obstructive Pulmonary Disease in Former Smokers: A Phase 3 Randomized Controlled Trial | Sanofi-Aventis Recherche & Developpement | Phase III | Not Recruiting | Mar 2021 | Jun 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Itepekimab | 2 | Unknown | 2021-03-22 | 2024-05-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.